New Triple-Action weight loss drug enters first human safety tests
NCT ID NCT07205432
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new injection called XTL6001 in 80 healthy and obese adults. The main goal is to check safety and how the body processes the drug. Researchers will also look at weight changes, but the study is too small to prove effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- XTL6001 injection (a triple-target GLP-1 receptor agonist for weight management)
- What this could lead to
- If successful, this could lead to a new injectable medication for weight loss and metabolic disease management.
- What could go wrong
- This is an early Phase 1 trial with only 80 participants, focused on safety. It is too small and early to know if XTL6001 will be effective or have serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WEIGHT MANAGEMENT IN ADULT PATIENTS WITH OBESITY OR OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Shijitan Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100038, China
Contact Phone: •••-•••-•••• Email: •••••@•••••